Novo Drug Patent Portfolio

Novo's Family Patents

Title	Lead Sponsor	Collaborators	Status	Phases

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes	Novo Nordisk A/S	NA	RECRUITING (Sep, 2024)	PHASE3
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice	Novo Nordisk A/S	NA	COMPLETED (Sep, 2024)
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)	Novo Nordisk A/S	NA	ACTIVE NOT RECRUITING (Sep, 2024)	PHASE3
A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy	Novo Nordisk A/S	NA	ENROLLING BY INVITATION (Oct, 2023)
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People	Novo Nordisk A/S	NA	COMPLETED (Jun, 2023)	PHASE1
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes	Novo Nordisk A/S	NA	COMPLETED (Jul, 2022)	PHASE3
A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes	Novo Nordisk A/S	NA	COMPLETED (Aug, 2018)	PHASE1

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List